Clinical Evidence: CB4 Derma was clinically tested in a limited trial of 4 weeks. The results showed consistent improvement in hydration, reduction in the level of redness as well disappearance of inflamed red skin (erythema) after repeated use.
Scientific Evidence: CBD has decrease inflammation of skin cells, decrease signalling of immune cells responsible for inflammation, and may decrease skin cell turnover and overgrowth. These properties are desirable to help control skin conditions such of eczema and psoriasis.
References:
Baswan SM et al. Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders. Clinical Cosmetic and Investigational Dermatology 2020;13:927–42.
https://pubmed.ncbi.nlm.nih.gov/33335413/
Casares L et al. Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biology 2020;28:101321.
https://pubmed.ncbi.nlm.nih.gov/31518892/
Casiraghi A et al. Topical Administration of Cannabidiol: Influence of Vehicle-Related Aspects on Skin Permeation Process. Pharmaceuticals 2020;13:337.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690861/
Chelliah MP et al. Self-initiated use of topical cannabidiol oil for epidermolysis bullosa. Pediatric Dermatology 2018;1–4.
https://pubmed.ncbi.nlm.nih.gov/29786144/
Eagelston LRM et al. Cannabinoids in dermatology: a scoping review. Dermatology Online Journal 2018;|24(6):1.
https://pubmed.ncbi.nlm.nih.gov/30142706/
Internal Clinical study NCT04045314: Effect of CB4 Derma (0.5% cannabidiol and 1% hemp oil) on skin hydration and erythema. 2019.
Jarocka‐Karpowicz I et al. Cannabidiol Effects on Phospholipid Metabolism in Keratinocytes from Patients with Psoriasis Vulgaris. Biomolecules 2020;10:367.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175188/
Jastrza A et al. Cannabidiol Regulates the Expression of Keratinocyte Proteins Involved in the Inflammation Process through Transcriptional Regulation. Cells 2019;8:827.
https://pubmed.ncbi.nlm.nih.gov/31382646/
Kupczyk P et al. Cannabinoid system in the skin – a possible target for future therapies in dermatology. Experimental Dermatology 2009;18:669–79.
https://pubmed.ncbi.nlm.nih.gov/19664006/
Nam G et al. Selective Cannabinoid Receptor-1 Agonists Regulate Mast Cell Activation in an Oxazolone-Induced Atopic Dermatitis Model. Ann Dermatol 2016;28(1):22-9.
https://pubmed.ncbi.nlm.nih.gov/26848215/
National Eczema Association. Get the Facts: CBD (Accessed July 13, 2021)
https://nationaleczema.org/get-the-facts-cbd/
Proksch E et al. Modulators of the endocannabinoid system influence skin barrier repair, epidermal proliferation, differentiation and inflammation in a mouse model. Experimental Dermatology 2019;28:1058–65.
https://pubmed.ncbi.nlm.nih.gov/31350927/
Jhawar N et al. The growing trend of cannabidiol in skincare products. Clinics in Dermatology 2019;37, 279–81.
https://pubmed.ncbi.nlm.nih.gov/31178109/
Sangiovanni E et al. Cannabis sativa L. extract and cannabidiol inhibit in vitro mediators of skin inflammation and wound injury. Phytotherapy Research. 2019;1–11.
https://pubmed.ncbi.nlm.nih.gov/31250491/
Clinical Evidence: CB4 Derma was clinically tested in a limited trial of 4 weeks. The results showed consistent improvement in hydration, reduction in the level of redness as well disappearance of inflamed red skin (erythema) after repeated use.
Scientific Evidence: CBD decreases inflammation in skin cells, decrease signalling of immune cells responsible for inflammation. CBD has shown to have effects at the molecular level to decrease inflammation through FAAH inhibition and indirect modulation of CB2 receptors, decrease in pro-inflammatory cytokine release, inhibiting T cell proliferation, and reducing migration and adhesion of immune cells among other biological pathways. CBD has also show to decrease skin cell turnover and overgrowth. These properties are desirable in helping to control skin conditions such of eczema and psoriasis.
References:
Baswan SM et al. Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders. Clinical Cosmetic and Investigational Dermatology 2020;13:927–42.
https://pubmed.ncbi.nlm.nih.gov/33335413/
Casares L et al. Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biology 2020;28:101321.
https://pubmed.ncbi.nlm.nih.gov/31518892/
Casiraghi A et al. Topical Administration of Cannabidiol: Influence of Vehicle-Related Aspects on Skin Permeation Process. Pharmaceuticals 2020;13:337.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690861/
Chelliah MP et al. Self-initiated use of topical cannabidiol oil for epidermolysis bullosa. Pediatric Dermatology 2018;1–4.
https://pubmed.ncbi.nlm.nih.gov/29786144/
Eagelston LRM et al. Cannabinoids in dermatology: a scoping review. Dermatology Online Journal 2018;|24(6):1.
https://pubmed.ncbi.nlm.nih.gov/30142706/
Internal Clinical study NCT04045314: Effect of CB4 Derma (0.5% cannabidiol and 1% hemp oil) on skin hydration and erythema. 2019.
Jarocka‐Karpowicz I et al. Cannabidiol Effects on Phospholipid Metabolism in Keratinocytes from Patients with Psoriasis Vulgaris. Biomolecules 2020;10:367.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175188/
Jastrza A et al. Cannabidiol Regulates the Expression of Keratinocyte Proteins Involved in the Inflammation Process through Transcriptional Regulation. Cells 2019;8:827.
https://pubmed.ncbi.nlm.nih.gov/31382646/
Kupczyk P et al. Cannabinoid system in the skin – a possible target for future therapies in dermatology. Experimental Dermatology 2009;18:669–79.
https://pubmed.ncbi.nlm.nih.gov/19664006/
Nam G et al. Selective Cannabinoid Receptor-1 Agonists Regulate Mast Cell Activation in an Oxazolone-Induced Atopic Dermatitis Model. Ann Dermatol 2016;28(1):22-9.
https://pubmed.ncbi.nlm.nih.gov/26848215/
National Eczema Association. Get the Facts: CBD (Accessed July 13, 2021)
https://nationaleczema.org/get-the-facts-cbd/
Proksch E et al. Modulators of the endocannabinoid system influence skin barrier repair, epidermal proliferation, differentiation and inflammation in a mouse model. Experimental Dermatology 2019;28:1058–65.
https://pubmed.ncbi.nlm.nih.gov/31350927/
Jhawar N et al. The growing trend of cannabidiol in skincare products. Clinics in Dermatology 2019;37, 279–81.
https://pubmed.ncbi.nlm.nih.gov/31178109/
Sangiovanni E et al. Cannabis sativa L. extract and cannabidiol inhibit in vitro mediators of skin inflammation and wound injury. Phytotherapy Research. 2019;1–11.
https://pubmed.ncbi.nlm.nih.gov/31250491/
Recent Comments